Ablynx expansion further fuel for Merck's immuno-oncology ambitions
This article was originally published in Scrip
Executive Summary
Merck & Co is expanding its immuno-oncology collaboration with Ablynx of Belgium to address an increased number of immune checkpoint modulator targets.